Budget 2024: As Finance Minister Nirmala Sitharaman will table the Union Budget 2024 later this month, industry leaders from the pharmaceutical sector are demanding renewed focus on the industry.
Orchid Pharma Limited (Orchid Pharma) announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. Chennai-based Orchid Pharma has partnered with Cipla Limited (Cipla) to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India.
Orchid Pharma, based in Chennai, has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam.
Chennai-based Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity active pharmaceutical ingredient (API), enmetazobactam.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Advanz Pharma’s combined antibiotic, cefepime/enmetazobactam, to treat complicated infections.
CHICAGO--(BUSINESS WIRE)--Xentria Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, and Meitheal Pharmaceuticals, Inc.1, today announced an exclusive multi-year licensing agreement to commercialize its lead candidate, and novel biologic, XTMAB-16 for pulmonary sarcoidosis in North America.